

SUPPLEMENTAL DISCLOSURE – ACQUISITION OF COMPANY

Aoxing Pharmaceutical Company, Inc.
Flat F, 9/F, Block 25, South Horizons,
Apleichau, Hong Kong

+852 9491-2348

frankiecflo@outlook.com

The goal of this disclosure is to provide information with respect to the company's acquisition of Hong Kong's InfoEd Tech Limited and a complete strategic shift from pharmaceutical development to Educational Technology (EdTech).

On June 18, 2025, Aoxing Pharmaceutical Company, Inc. acquired Hong Kong's InfoEd Tech Limited, a premier educational technology firm. The acquisition of InfoEd Tech Limited aligns with AOXG's mission to provide high-quality educational resources tailored to the diverse linguistic landscape of the Asia Pacific. Dr. Lo's extensive experience as a trainer has revealed that language barriers significantly hinder learning opportunities for many citizens in the region. By converting training programs into video formats and utilizing AI for multilingual support, AOXG aims to democratize access to education, enabling learners to benefit from global expertise.

As part of this transition, AOXG will discontinue its previous operations in the development, manufacturing, and marketing of active pharmaceutical ingredients for narcotics and neurological drugs. Instead, the company will focus on providing innovative educational technology solutions aimed at overcoming language barriers in the Asia Pacific region.

I, Dr. Frankie Lo, being the CEO of Aoxing Pharmaceutical Company, Inc. certify that:

I have read the forgoing and it is true and correct.

June 21, 2025

/s/ Dr. Frankie Lo
Dr. Frankie Lo, CEO